TearSolutions
- Company typePrivate
- Founded2015
- HeadquartersCharlottesville, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
TearSolutions firmographics
Firmographics- Name
- TearSolutions
- Legal name
- TearSolutions, Inc.
- Website
- https://tearsolutions.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TearSolutions industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where TearSolutions is headquartered
LocationHeadquarters
- HQ city
- Charlottesville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TearSolutions business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue biotech company developing Lacripep as an investigational new drug. Once FDA approved, the company will generate revenue through prescription pharmaceutical sales for ocular surface diseases including dry eye disease, neurotrophic keratitis, and primary Sjögren's Syndrome-associated ocular surface disease.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
TearSolutions product offering
Product offeringCore offering
TearSolutions develops Lacripep, a first-in-class synthetic peptide therapy derived from the naturally occurring tear protein Lacritin. It is a topical therapy that preserves all of Lacritin's bioactivity in a short stable peptide producible at scale, targeting ocular surface diseases including dry eye disease, neurotrophic keratitis, and primary Sjögren's Syndrome-associated ocular surface disease.
Product overview
TearSolutions is a biotechnology company with a single core product: Lacripep™. Lacripep is a proprietary first-in-class synthetic peptide therapy derived from the tear protein lacritin, developed as a topical treatment for ocular surface disease including dry eye disease, primary Sjögren's Syndrome, and neurotrophic keratitis. The company has completed a first-in-human Phase I/II clinical trial and is currently conducting a Phase IIb trial and a Phase 2 trial for neurotrophic keratitis following FDA Orphan Drug and Fast Track Designations.
Differentiator
Problem solved
Functional benefit
Products and services
- Lacripep A proprietary first-in-class synthetic peptide therapy derived from the tear protein lacritin, designed as a topical treatment for ocular surface disease. It preserves all of Lacritin's bioactivity in a short stable peptide that can be produced at scale, targeting nerve damage in the eye and restoring corneal health in patients with dry eye disease, neurotrophic keratitis, and primary Sjögren's Syndrome.
Quantifiable outcome
- Statistically significant improvement in both sign and symptom at two weeks in Phase I/II trial
- +2 more outcomes
Companies that use TearSolutions
Customer profileSegments4 records
Ideal customer profiles3 records
TearSolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TearSolutions partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights5 records
TearSolutions competitors and assessment
Company assessmentBroad incumbents
- Bausch + Lomb: Large ophthalmology incumbent that owns Xiidra (lifitegrast) for dry eye disease and Miebo for evaporative DED, representing the dominant commercial competitor in TearSolutions' target market.
- AbbVie (Allergan Aesthetics): Owns Restasis (cyclosporine ophthalmic), the historical blockbuster dry eye therapy, representing the largest incumbent competitor and benchmark for the DED market TearSolutions is targeting.
Emerging players
- RegeneRx Biopharmaceuticals: Clinical-stage biotech developing thymosin beta-4-based peptide therapies for ophthalmic indications including dry eye, comparable to TearSolutions as a small peptide-platform ophthalmology company.
- Stuart Therapeutics: Early-stage biotech developing collagen mimetic peptide therapies for ocular surface disease, with a similar peptide-based therapeutic approach to TearSolutions' Lacripep.
- Aerie Pharmaceuticals: Ophthalmology-focused biotech developing therapies for ocular surface diseases including dry eye, comparable as a small specialized ophthalmic therapeutics developer (acquired by Alcon in 2022).
- Palatin Technologies: Clinical-stage biotech developing PL9643 for dry eye disease, a melanocortin receptor agonist with a Phase 2/3 asset directly overlapping TearSolutions' target indications.
Direct peers
- Aldeyra Therapeutics: Clinical-stage biotech developing novel small-molecule therapies for dry eye disease and other inflammatory ocular conditions, directly competing with TearSolutions for the same patient population with a Phase 3 asset (reproxalap).
- Oyster Point Pharma: Commercial-stage company developing Tyrvaya (varenicline nasal spray) for dry eye disease, a direct competitor in the ocular surface disease space with a recently approved therapy.
- Kala Pharmaceuticals: Ophthalmology-focused biotech that developed and commercialized Eysuvis for dry eye disease, directly comparable to TearSolutions as a small ophthalmic biotech targeting ocular surface disease.
- Mitotech Pharma: Clinical-stage biotech developing SkQ1 (plastoquinone) for dry eye disease, directly competing with TearSolutions as a small company advancing novel mechanism therapies through Phase 2/3 in the same indication.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
TearSolutions social profiles
Digital presenceTearSolutions compliance and trust
Trust signalCompliance2 records
TearSolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
TearSolutions leadership team
Management profileNumber of profiles
Profiles7 records
TearSolutions funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TearSolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TearSolutions
What does TearSolutions do?
TearSolutions develops Lacripep, a first-in-class synthetic peptide therapy derived from the naturally occurring tear protein Lacritin. It is a topical therapy that preserves all of Lacritin's bioactivity in a short stable peptide producible at scale, targeting ocular surface diseases including dry eye disease, neurotrophic keratitis, and primary Sjögren's Syndrome-associated ocular surface disease.
Is TearSolutions a public or private company?
TearSolutions is a private company. It is classified as venture growth investor backed and is currently operating.
When was TearSolutions founded?
TearSolutions was founded in 2015. It employs 1 to 10 people.
Where is TearSolutions based?
TearSolutions is headquartered in Charlottesville, United States, in the North America region.
How does TearSolutions make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are TearSolutions's main competitors?
Broad incumbents on record are Bausch + Lomb and AbbVie (Allergan Aesthetics). Emerging players are RegeneRx Biopharmaceuticals, Stuart Therapeutics, Aerie Pharmaceuticals and Palatin Technologies. Direct peers are Aldeyra Therapeutics, Oyster Point Pharma, Kala Pharmaceuticals and Mitotech Pharma.
Does TearSolutions have an API?
No public API is recorded for TearSolutions.
What industry is TearSolutions in?
TearSolutions's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its SIC code is 8090.